[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 22, Issue 4 (Bimonthly 2018) ::
Feyz 2018, 22(4): 387-394 Back to browse issues page
Association of adiponectin rs17300539 gene polymorphism with a non-alcoholic fatty liver disease in an Iranian population
Fahimeh Rezaei , Masoumeh Nezhadali * , Mehdi Hedayati
Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, I. R. Iran. , ma_nejadali@yahoo.com
Abstract:   (262 Views)

Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disorder, resulting from exceeding fat cumulating in the liver .Adiponectin, a protein secreted from the adipose tissue, reduces liver inflammation. In this study, the relationship between adiponectin rs17300539 gene polymorphism and a non-alcoholic fatty liver disease was investigated.
Materials and Methods: This case-control study was conducted on 80 subjects with NAFLD and 80 healthy subjects. The determination of polymorphism rs17300539 of adiponectin gene was performed by the PCR-RFLP method and electrophoresis technique. The plasma levels of adiponectin and insulin hormones were measured by an enzyme-linked immunosorbent assay (ELISA) kit.
Results: The results showed that there was no significant difference in allele frequencies between the two groups of the case and control (P>0.05). The body mass index (BMI) in genotype GA carriers was higher than that of genotype GG carriers (P<0.05). Moreover, the diastolic blood pressure in the male patients carrying the genotype GA was higher than that in the genotype GG carriers (P<0.05). In the female patients carrying the genotype GA, the AST and triglyceride levels were higher than the GG female carriers (P<0.05). 
Conclusion: It seems that the allele G can be beneficial in reducing the side-effects of the non-alcoholic fatty liver disease.
Keywords: Non-alcoholic fatty liver, Adiponectin, Polymorphism, Adipose tissue
Full-Text [PDF 264 kb]   (12 Downloads)    
Type of Study: Research | Subject: General
Received: 2017/11/8 | Accepted: 2018/06/20 | Published: 2018/10/6
1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313(22): 2263–73.
2. Brunt EM, Wong VW, Nobili V, Day CP, Soo‌koian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 1: 15080.
3. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver trans‌plantation in the United States. Gastroenterology 2015; 148(3): 547–55.
4. Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci 2016; 61(5): 1226–33.
5. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016; 64(5): 1577–86.
6. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 2016; 8(2): 101–9.
7. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in non‌alcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13(4): 643–54.
8. Robinson K, John Prins J, Venkatesh B. Clinical review: Adiponectin biology and its role in inflammation and critical illness. Crit Care 2011; 15(2): 221.
9. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 2016; 63(1): 138–47.
10. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concen‌trations of adiponectin, an adipose-derived protein. Diabetes 2001; 50(9): 2094-9.
11. Reeves HL, Zaki MY, Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci 2016; 61(5): 1234–45.
12. Wei Z, Li-Oun Z, Xiao-ling H, Jian Q. Guoyue Y. Association of adiponectin gene polymorphism and additional gene–gene interaction with non‌alcoholic fatty liver disease in the Chinese Han poplation. Hepatol INT 2016; 10(3): 511-17.
13. Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016; 14(1): 124–31.
14. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388–402.
15. Zhou Y, Oresic M, Leivonen M, Gopa‌lacharyulu P, Hyysalo J, Arola J, et al. Noninvasive dete‌ction of nonalcoholic steatohepatitis using clin‌ical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol 2016; 14(10): 1463–72.
16. Loomba R, Quehenberger O, Armando A, Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res 2015; 56(1): 185–92.
17. Kaswala DH, Lai M, Afdhal NH. Fibrosis asse‌ssment in nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2016; 61(5): 1356-64.
18. Neuschwander-Tetri BA. Non-alcoholic Fatty Liver Disease. BMC-Med 2017; 15(1): 45.
19. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149(2): 389–97.
20. Paouri E, Tzara O, Kartalou GI, Zenelak S, Georgopoulos S. Peripheral Tumor Necrosis Factor-alpha (TNF-α) modulates amyloid pathology by regulating blood-derived immune cells and glial response in the brain of AD/TNF transgenic mice. J Neurosci 2017; 37(20): 2484-16.
21. Polyzos SA. Kountouras J. Nonalocohlic fatty liver diseases and adipokines: a novel role for fat imbalance. Immuno-Gastroenterol 2014; 2: 129-31.
22. Henneman P, Aulchenko YS, Frants RS, Zor‌kol‌tseva IV, Zillikens MC, Frolich ME, et al. Gentic architecture of plasma adiponectin overlaps with the genetics of metabolicm syndrome. Diabet Car 2010; 33(4): 908-13.
23. Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS, et al. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 2008; 57(12): 3353-9.
24. Li Y, Liu L, Wang B, Wang J, Chen D. Me‌t‌‌formin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2013; 1(1): 57–64.
25. Morandi A, Maffeis C, Lobbens, Bouatia-Najin, Huede B, Pineil D, F roquelp, Early deter‌imental metabolic outcomes of rs17300539- A alleie of AdipoQ gene despite higher adipo‌nec‌tonemia. Obesity 2010; 18(7): 1469-73.
26. Souvik Ghatak, Rajendra Bose Muthukumaran, and Senthil Kumar Nachimuthu, Author information Copyright and License information. A Simple Method of Genomic DNA Extraction from Human Samples for PCR-RFLP Analysis. J Biomol Tech 2013; 24(4): 224–31.
27. Wassel CL, Pankow JS, Jacobs Jr DR, Steffes MW, Li NA, Schreiner PJ. Variants in the adiponectin gene and serum adiponectin: the Coronary Artery Development in Young Adults (CARDIA) Study. Obesity 2010; 18(12): 2333-8.
28. Vasseur F, Helbecque N, Lobbens S, Vasseur-Delannoy V, Dina C, Clement C, et al. Hypo‌adipo‌nectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 2005; 48(5): 892–99.
29. Menzaghi C, Ercolino T, Salvemini L, Coco A, Fini G, Di Paola R, et al. Multigenic control of ser‌um adiponectin levels: evidence for a role of the APM1 gene and a locus on 14q13. Physiol Genomic 2005; 19(2): 170–4.
30. Morandi A, Maffeis C, Lobbens S, Bouatia-Naji N, Heude B, Pinelli L, et al. Early detrimental metabolic outcomes of rs17300539-A Allele of ADIPOQgene despite higher adiponectinemia. Obesity 2010; 18(7): 1469–73.
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rezaei F, Nezhadali M, Hedayati M. Association of adiponectin rs17300539 gene polymorphism with a non-alcoholic fatty liver disease in an Iranian population. Feyz. 2018; 22 (4) :387-394
URL: http://feyz.kaums.ac.ir/article-1-3463-en.html

Volume 22, Issue 4 (Bimonthly 2018) Back to browse issues page
مجله علمی پژوهشی فیض ::: دانشگاه علوم پزشکی کاشان KAUMS Journal ( FEYZ )
Persian site map - English site map - Created in 0.06 seconds with 31 queries by YEKTAWEB 3764